FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, ...

FUJIFILM has invested about $4 billion in building biopharmaceutical manufacturing sites and life sciences capabilities.

Ahead of its scheduled opening later this year, the massive Fujifilm Diosynth Biotechnologies manufacturing plant in Holly ...

The agreement is valued at over $3 billion and increases U.S. manufacturing capacity to help ensure patient access to ...

Agreement secures additional U.S. manufacturing capacity to help ensure patient access to medicine HOLLY SPRINGS, N.C., April 23, 2025-- FUJIFILM Diosynth Biotechnologies, a world-leading contract ...

As pharma giants line up one after another to tout their investment plans in the U.S., Regeneron is adopting a different tack ...

FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year ...

Regeneron to invest over $3 billion to boost US manufacturing Regeneron Pharmaceuticals said on Tuesday it has signed a deal worth more than $3 billion with contract drug developer Fujifilm ...

FUJIFILM Diosynth Biotechnologies, a global contract development and manufacturing organization (CDMO) with major operations ...

Regeneron Pharmaceuticals Inc. agreed to pay Fujifilm Diosynth Biotechnologies more than $3 billion over the next decade to ...

Under the terms of the agreement, FUJIFILM Diosynth Biotechnologies will provide US-based manufacturing for Regeneron over the 10-year period through current and planned expansions at its new ...